Seroatlas · Human Serome Atlas

ZPLD1

Zona pellucida-like domain-containing protein 1

Also known as: ZPLD1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8TCW7
Gene: ZPLD1
Ensembl: ENSG00000170044
Chromosome: 3
Canonical length: 415 aa
Protein class: Predicted membrane proteins
Subcellular location: Nucleoplasm
Secretome location: Intracellular and membrane

OverviewNCBI Gene

Predicted to act upstream of or within vestibular reflex. Predicted to be located in cytoplasmic vesicle membrane and extracellular region. Predicted to be active in cell surface and extracellular space. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

415 residues, UniProt reviewed canonical sequence.

>Q8TCW7|ZPLD1
     1  MEQIWLLLLL TIRVLPGSAQ FNGYNCDANL HSRFPAERDI SVYCGVQAIT MKINFCTVLF
    61  SGYSETDLAL NGRHGDSHCR GFINNNTFPA VVIFIINLST LEGCGNNLVV STIPGVSAYG
   121  NATSVQVGNI SGYIDTPDPP TIISYLPGLL YKFSCSYPLE YLVNNTQLAS SSAAISVREN
   181  NGTFVSTLNL LLYNDSTYNQ QLIIPSIGLP LKTKVFAAVQ ATNLDGRWNV LMDYCYTTPS
   241  GNPNDDIRYD LFLSCDKDPQ TTVIENGRSQ RGRFSFEVFR FVKHKNQKMS TVFLHCVTKL
   301  CRADDCPFLM PICSHRERRD AGRRTTWSPQ SSSGSAVLSA GPIITRSDET PTNNSQLGSP
   361  SMPPFQLNAI TSALISGMVI LGVTSFSLLL CSLALLHRKG PTSLVLNGIR NPVFD

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ZPLD1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.37
Highest tissue expression: 2.3 nTPM

Expression across tissuesHPA

Tissue

retina: 2.3 nTPM
gallbladder: 2.1 nTPM
duodenum: 0.8 nTPM
ovary: 0.8 nTPM
testis: 0.6 nTPM
kidney: 0.4 nTPM

Single-cell type

papillary tip epithelial cells: 78 nCPM
late primary spermatocytes: 70 nCPM
early spermatids: 64 nCPM
epicardial cells: 48 nCPM
renal collecting duct principal cells: 46 nCPM
late spermatids: 44 nCPM

Immune cell

non-classical monocyte: 0.6 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

medulla oblongata: 3.8 nTPM
cerebellum: 3 nTPM
pons: 2.1 nTPM
hypothalamus: 1.2 nTPM
basal ganglia: 1.1 nTPM
cerebral cortex: 1.1 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.01
gnomAD pLI: 0
gnomAD missense Z: -0.24
DepMap mean gene effect: 0.03
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

vestibular reflex

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ZPLD1 as an antibody target. Whether an autoantibody or antibody against ZPLD1 could matter depends on whether native ZPLD1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ZPLD1 is annotated as secreted, so native ZPLD1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label ZPLD1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...